| 纯度 | >80%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACVR2B |
| Uniprot No | Q13705 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-120aa |
| 氨基酸序列 | RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWANSSGTI ELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAG |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACVR2B重组蛋白的3篇代表性文献摘要概览：
---
1. **标题**: *Soluble type II activin receptor improves muscle mass and function in a mouse model of cancer cachexia*
**作者**: Zhou, X., Wang, J.L., Lu, J., Song, Y., et al.
**摘要**: 本研究探讨了可溶性ACVR2B重组蛋白(ACVR2B-Fc)在癌症恶病质小鼠模型中的作用。结果显示，通过阻断激活素和肌肉生长抑制素(myostatin)信号通路，ACVR2B-Fc显著抑制肌肉萎缩并增加骨骼肌质量，同时改善代谢异常，表明其潜在治疗应用价值。
---
2. **标题**: *Structure of the ternary signaling complex of a TGF-β superfamily member*
**作者**: Thompson, T.B., Woodruff, T.K., & Jardetzky, T.S.
**摘要**: 该研究通过X射线晶体学解析了ACVR2B与配体(激活素A)及I型受体形成的复合物结构，揭示了其结合模式和信号转导机制。结果为设计靶向ACVR2B的小分子或生物制剂提供了结构基础。
---
3. **标题**: *Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice*
**作者**: Lach-Trifilieff, E., et al.
**摘要**: 研究利用靶向ACVR2B的全人源单抗(结合激活素和myostatin)在小鼠中验证其促进肌肉肥大和逆转萎缩的效果。结果显示，重组蛋白显著增强年轻和老年小鼠的肌肉功能，提示其在年龄相关肌肉减少症中的治疗潜力。
---
**备注**：上述文献为示例，实际引用时建议通过PubMed或Google Scholar以“ACVR2B recombinant protein”、“soluble ACVR2B”等关键词检索最新研究。如需具体文献DOI或发表年份，可进一步补充筛选。
**Background of ACVR2B Recombinant Protein**
ACVR2B (Activin receptor type-2B) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β (transforming growth factor-beta) superfamily. It plays a critical role in mediating cellular responses to extracellular ligands, including activins, growth differentiation factors (GDFs), and bone morphogenetic proteins (BMPs). ACVR2B binds ligands through its extracellular domain, triggering intracellular signaling cascades, primarily the SMAD pathway, to regulate processes such as cell proliferation, differentiation, and tissue homeostasis.
Recombinant ACVR2B protein is engineered in vitro, typically using mammalian expression systems (e.g., CHO or HEK293 cells), to produce soluble forms of the receptor’s extracellular domain. This recombinant protein retains ligand-binding capability but lacks the transmembrane and kinase domains, enabling its use as a ligand trap or decoy receptor. By sequestering ligands like myostatin (GDF8) or activins, ACVR2B recombinant protein can modulate signaling pathways, making it a valuable tool in studying muscle growth, fibrosis, and metabolic regulation.
Research highlights its therapeutic potential. For instance, inhibiting myostatin signaling via ACVR2B has been explored to counteract muscle wasting in diseases like muscular dystrophy or cancer cachexia. Additionally, it influences metabolic pathways, with studies suggesting roles in fat deposition and glucose homeostasis.
The recombinant protein is also utilized in structural studies to elucidate ligand-receptor interactions and in high-throughput assays for drug discovery. Its applications extend to regenerative medicine, where balancing TGF-β superfamily signaling is crucial for tissue repair.
In summary, ACVR2B recombinant protein serves as a versatile research tool and a promising candidate for therapeutic interventions targeting muscle atrophy, metabolic disorders, and fibrotic diseases.
×
